Voyageur Pharmaceuticals Ltd. (VM.V)
CAD 0.11
(50.0%)
CAD 0.11
(50.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 40 Thousand CAD | 56.74% |
| 2022 | 25.52 Thousand CAD | -39.35% |
| 2021 | 42.07 Thousand CAD | -84.32% |
| 2020 | 268.4 Thousand CAD | 93.62% |
| 2019 | 138.62 Thousand CAD | -22.83% |
| 2018 | 179.64 Thousand CAD | 260.22% |
| 2017 | 49.87 Thousand CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 40 Thousand CAD | 0.0% |
| 2024 Q1 | 40 Thousand CAD | 0.0% |
| 2024 Q3 | - CAD | 0.0% |
| 2023 Q2 | 25.52 Thousand CAD | 0.0% |
| 2023 Q3 | 25.52 Thousand CAD | 0.0% |
| 2023 Q4 | 40 Thousand CAD | 56.74% |
| 2023 FY | 40 Thousand CAD | 56.74% |
| 2023 Q1 | 25.52 Thousand CAD | 0.0% |
| 2022 Q3 | 34.28 Thousand CAD | -11.93% |
| 2022 Q4 | 25.52 Thousand CAD | -25.56% |
| 2022 FY | 25.52 Thousand CAD | -39.35% |
| 2022 Q1 | 40.51 Thousand CAD | -3.71% |
| 2022 Q2 | 38.92 Thousand CAD | -3.92% |
| 2021 Q1 | 117.14 Thousand CAD | -56.36% |
| 2021 Q2 | 52.47 Thousand CAD | -55.2% |
| 2021 Q3 | 50.99 Thousand CAD | -2.81% |
| 2021 Q4 | 42.07 Thousand CAD | -17.49% |
| 2021 FY | 42.07 Thousand CAD | -84.32% |
| 2020 Q3 | 222.98 Thousand CAD | 2.53% |
| 2020 Q2 | 217.49 Thousand CAD | 165.77% |
| 2020 Q1 | 81.83 Thousand CAD | -40.97% |
| 2020 FY | 268.4 Thousand CAD | 93.62% |
| 2020 Q4 | 268.4 Thousand CAD | 20.37% |
| 2019 Q2 | 139 Thousand CAD | -22.81% |
| 2019 FY | 138.62 Thousand CAD | -22.83% |
| 2019 Q4 | 138.62 Thousand CAD | -0.15% |
| 2019 Q3 | 138.84 Thousand CAD | -0.12% |
| 2019 Q1 | 180.07 Thousand CAD | 0.24% |
| 2018 Q3 | 139.38 Thousand CAD | 203.9% |
| 2018 Q1 | 47.88 Thousand CAD | -3.99% |
| 2018 FY | 179.64 Thousand CAD | 260.22% |
| 2018 Q4 | 179.64 Thousand CAD | 28.89% |
| 2018 Q2 | 45.86 Thousand CAD | -4.22% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 FY | 49.87 Thousand CAD | 0.0% |
| 2017 Q4 | 49.87 Thousand CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | 5.06 Million CAD | 99.21% |
| CanadaBis Capital Inc. | 7.3 Million CAD | 99.453% |
| Decibel Cannabis Company Inc. | 40.96 Million CAD | 99.902% |
| Delivra Health Brands Inc. | 2.02 Million CAD | 98.027% |
| Entourage Health Corp. | 161.58 Million CAD | 99.975% |
| Lifeist Wellness Inc. | 1.26 Million CAD | 96.84% |
| Cannara Biotech Inc. | 45.78 Million CAD | 99.913% |
| Medicure Inc. | 544 Thousand CAD | 92.647% |
| PharmaCielo Ltd. | 18.3 Million CAD | 99.782% |
| Rubicon Organics Inc. | 10.25 Million CAD | 99.61% |
| BioSyent Inc. | 1.22 Million CAD | 96.724% |